Abstracts tagged "Malignancy and systemic lupus erythematosus (SLE)"

Abstract Number: 710 • ACR/ARHP Annual Meeting 2018
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Basile Tessier-Cloutier¹, David Twa², Eva Baecklund³, Randy Gascoyne⁴, Nathalie A. Johnson⁵, Carin Backlin³, Diane L. Kamen⁶, Ann E. Clarke⁷, Rosalind Ramsey-Goldman⁸, Jennifer LF Lee⁹, Pedro Farinha⁴ and Sasha Bernatsky¹⁰, ¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, ⁵Department of Oncology, McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸FSM, Northwestern University, Chicago, IL, ⁹Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…
Abstract Number: 1606 • ACR/ARHP Annual Meeting 2017
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Sasha Bernatsky¹, Murray Urowitz², John G Hanly³, Ann E. Clarke⁴, Marvin J. Fritzler⁵, Caroline Gordon⁶, Juanita Romero-Diaz⁷, Graciela S. Alarcón⁸, Sang-Cheol Bae⁹, Michelle Petri¹⁰, Joan T. Merrill¹¹, Daniel J. Wallace¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, David A. Isenberg¹⁵, Anisur Rahman¹⁶, Susan Manzi¹⁷, Ola Nived¹⁸, Gunnar K. Sturfelt¹⁹, Christine A. Peschken²⁰, Jorge Sanchez-Guerrero²¹, Guillermo Ruiz-Irastorza²², Cynthia Aranow²³, Ronald F van Vollenhoven²⁴, Asad Zoma²⁵, Kristján Steinsson²⁶, Munther A Khamashta²⁷, Ellen M. Ginzler²⁸, Anca Askanase²⁹, Kenneth C. Kalunian³⁰, Mary Anne Dooley³¹, S. Sam Lim³², Diane L. Kamen³³, Søren Jacobsen³⁴, Manuel Ramos-Casals³⁵, Murat Inanc³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹⁰Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁸Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁰RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²²Biocruces Health Research Institute, Barakaldo, Spain, ²³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²⁴AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁵University of Glasgow, Glaskow, United Kingdom, ²⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁷Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁸Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹UNC Kidney Centre, Chapel Hill, NC, ³²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³⁵Hospital Clinic, Barcelona, Spain, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…
Abstract Number: 2990 • ACR/ARHP Annual Meeting 2016
Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Sasha Bernatsky¹, Murray Urowitz², John Hanly³, Ann E. Clarke⁴, Caroline Gordon⁵, Juanita Romero-Diaz⁶, Graciela S. Alarcon⁷, Sang-Cheol Bae⁸, Michelle Petri⁹, Joan T. Merrill¹⁰, Daniel J Wallace¹¹, Paul R. Fortin¹², Dafna D. Gladman¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Susan Manzi¹⁶, Ola Nived¹⁷, Gunnar K. Sturfelt¹⁸, Christine Peschken¹⁹, Jorge Sánchez-Guerrero²⁰, Guillermo Ruiz-Irastorza²¹, Cynthia Aranow²², Ronald F. van Vollenhoven²³, Asad Zoma²⁴, Kristján Steinsson²⁵, M Khamashta²⁶, Ellen M. Ginzler²⁷, Anca Askanase²⁸, Kenneth C. Kalunian²⁹, Mary Anne Dooley³⁰, S. Sam Lim³¹, Diane L. Kamen³², Søren Jacobsen³³, Manuel Ramos-Casals³⁴, Murat Inanc³⁵, Jeremy Labrecque³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of, ⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Université Laval, CHU de Québec, Québec, QC, Canada, ¹³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁶Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁷Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁸Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ¹⁹Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ²⁰Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ²¹Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ²⁴Hairmyres Hospital, Scotland, United Kingdom, ²⁵Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁶Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁷Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ²⁸NYU, Seligman Centre for Advanced Therapeutics, New York, NY, ²⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³⁰Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ³¹Medicine, Emory University School of Medicine, Atlanta, GA, ³²Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³³Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Internal Medicine, Istanbul University, Istanbul, Turkey, ³⁶Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ³⁷Clinical Epidemiology Rheum, McGill UHC/RVH, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: Published studies of cancer risk in SLE to date have never focussed solely on clinically confirmed, incident patients. Prior studies thus may not reflect the cancer…
Abstract Number: 719 • ACR/ARHP Annual Meeting 2015
Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
Basile Tessier Cloutier¹, Pedro Farinha², Sasha Bernatsky³, Eva Baecklund⁴, Ann E. Clarke⁵, Rosalind Ramsey-Goldman⁶, Randy Gascoyne⁷ and SLICC Investigators, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Pathology, BC Cancer Agency, Vancouver, BC, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden, ⁵Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ⁶Fsm # M300, SLICC, Chicago, IL, ⁷Pathology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Background/Purpose: SLE has been consistently associated with an increased incidence of malignant lymphoma, especially the DLBCL subtype. Since the last WHO classification of 2008 DLBCL…
Abstract Number: 763 • ACR/ARHP Annual Meeting 2015
Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma
Sasha Bernatsky^1,2, John Spinelli³, Patrick M. Gaffney⁴, Karin E Smedby⁵, Rosalind Ramsey-Goldman⁶, Sophia Wang⁷ and Ann E. Clarke⁸, ¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ³School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Fsm # M300, Northwestern University, Chicago, IL, ⁷Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁸Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: The determinants behind the increased risk of non-Hodgkin Lymphoma (NHL) in systemic lupus (SLE) are unclear. The most common type of NHL in SLE…
Abstract Number: 2791 • ACR/ARHP Annual Meeting 2014
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2570 • ACR/ARHP Annual Meeting 2012
Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment
Sasha Bernatsky¹, Ann E. Clarke², Karen H. Costenbader³, Murray B. Urowitz⁴, Dafna D. Gladman⁵, Paul R. Fortin⁶, Michelle Petri⁷, Susan Manzi⁸, D.A. Isenberg⁹, Anisur Rahman¹⁰, Daniel Wallace¹¹, Caroline Gordon¹², Christine Peschken¹³, Mary Anne Dooley¹⁴, E.M. Ginzler¹⁵, Cynthia Aranow¹⁶, Steven M. Edworthy¹⁷, Ola Nived¹⁸, Søren Jacobsen¹⁹, Guillermo Ruiz-Irastorza²⁰, Edward H. Yelin²¹, Susan G. Barr²², Irene Blanco²³, Candace H. Feldman²⁴ and R. Ramsey-Goldman²⁵, ¹Clinical Epidemiology, Systemic Lupus International Collaborating Clinics, Montreal, QC, Canada, ²Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto,, Toronto, ON, Canada, ⁵Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶University of Laval, Quebec, QC, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁰Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹¹Cedars-Sinai/UCLA, Los Angeles, CA, ¹²School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹³Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁵Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ¹⁶Feinstein Institute for Medical Research, Manhasset, NY, ¹⁷The University of Calgary, Calgary, AB, Canada, ¹⁸Department of Clinical Science, Lund University, Rheumatology, Lund, Sweden, ¹⁹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ²¹Medicine, UC San Francisco, San Francisco, CA, ²²University of Calgary, University of Calgary, Calgary, AB, Canada, ²³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁵Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: In systemic lupus (SLE), concern exists about immunosuppressive drugs and lymphoma risk, Yet, the relative influence of disease activity vs treatment, is unknown. Our objective…